Genetic Technology Alert. Drug for Oculopharyngeal Muscular Dystrophy Treatment Receives Orphan Drug Designation; Non-Viral CFTR-Based Gene Therapy for Cystic Fibrosis Patients; Breast Cancer Diagnostic Test in Europe
Genetic Technology Alert. Drug for Oculopharyngeal Muscular Dystrophy Treatment Receives Orphan Drug Designation; Non-Viral CFTR-Based Gene Therapy for Cystic Fibrosis Patients; Breast Cancer Diagnostic Test in Europe
RELEASE DATE
17-Jul-2015
17-Jul-2015
REGION
Global
Global
Research Code: D757-00-03-00-00
SKU: HC02733-GL-TA_19627
$250.00
Special Price $187.50 save 25 %
In stock
SKU
HC02733-GL-TA_19627
Description
This issue profiles a drug for oculopharyngeal muscular dystrophy treatment that receives orphan drug designation; non-viral CFTR-based gene therapy for cystic fibrosis patients, a breast cancer diagnostic test in Europe.
Table of Contents
In This Issue
- 1. DRUG FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY TREATMENT RECEIVES ORPHAN DRUG DESIGNATION
- 2. NON-VIRAL CFTR-BASED GENE THERAPY FOR CYSTIC FIBROSIS PATIENTS
- 3. BREAST CANCER DIAGNOSTIC TEST IN EUROPE
- 4. RECENT PATENTS IN GENETIC TESTS IN THE EUROPEAN UNION
- 5. TECHVISION 2015
Popular Topics
This issue profiles a drug for oculopharyngeal muscular dystrophy treatment that receives orphan drug designation; non-viral CFTR-based gene therapy for cystic fibrosis patients, a breast cancer diagnostic test in Europe.
No Index | No |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | D757-00-03-00-00 |
Is Prebook | No |
Ti Codes | D758 |